Clinical applications of PD-1-based therapy: a focus on pembrolizumab (MK-3475) in the management of melanoma and other tumor types

Tara C Gangadhar¹
April KS Salama²
¹Division of Hematology/Oncology, Department of Medicine, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, USA; ²Division of Medical Oncology, Department of Medicine, Duke University Medical Center, Durham, NC, USA

Abstract: Preclinical work has led to an increased understanding of the immunomodulatory mechanisms involved in the regulation of the antitumor response in a variety of tumor types. PD-1 (programmed death 1) appears to be a key checkpoint involved in immune suppression in the tumor microenvironment, even in diseases not previously thought to be sensitive to immune manipulation. More recently, the subsequent clinical development of PD-1-based therapy has resulted in a major breakthrough in the field of oncology. Pembrolizumab, a humanized highly selective IgG4 anti-PD-1 monoclonal antibody, was recently approved for the treatment of advanced melanoma based on promising early-phase clinical data. Encouraging results have also been seen in other malignancies, and PD-1-targeted therapies are likely to markedly change the treatment landscape. Future work will center on rationally designed combination strategies in order to potentiate the antitumor immune response and overcome mechanisms of resistance.

Keywords: PD-1, cancer, pembrolizumab, nivolumab, immunotherapy, antitumor activity

Introduction
Immune-directed therapies have recently demonstrated improved efficacy in several tumor types, with significant advances resulting from the development of PD-1 (programmed death 1)-blocking agents, including pembrolizumab (formerly MK-3475). Drugs with immune-mediated activity have been used for decades in oncology, with high-dose interleukin-2 (IL-2) having been approved for metastatic melanoma in 1998 and adjuvant interferon-α2B approved in 1995. More recently, the CTLA-4 blocking agent, ipilimumab, and the vaccine therapy sipuleucel-T have gained approvals as well; however, while a small number of patients do gain long-lasting clinical benefit with each of these agents, the overall survival benefit in all patients treated with these agents remains small and the potential toxicity is significant.

The initial reports of clinical activity with PD-1 blockade using novel investigational agents demonstrated the feasibility of high rates of durable responses with immune therapy in several tumor types, in addition to melanoma and renal cell carcinoma (RCC), which had long been considered to be potentially immune responsive. The great potential for clinical activity with highly effective immune-directed therapy across many tumor types has now been realized; several ongoing and recently completed clinical trials have focused on developing safe and effective single-agent and combination immune therapy strategies, including PD-1 blockade. The newly realized possibilities of long-term disease control, improved survival, and, perhaps, even cure with effective immune-directed therapies highlight the importance of modulating the immune system in the care of oncology patients.
Here we review the clinical development of PD-1-based therapy, with a particular focus on the PD-1-blocking agent, pembrolizumab, in the treatment of advanced cancer.

Mode of action and pharmacology of pembrolizumab

The PD-1 pathway is an immune regulatory mechanism (Figure 1). The discovery of PD-1 blockade as a potential mechanism of T-cell activation and antitumor activity was originally based on studies of T cells in chronic infection models. Activated T cells (defined by the expression of activation markers CD69, CD44, and CD62L) which were lacking effector function were initially described as key mediators underlying the mechanism of viral immune evasion. In the presence of chronic viral infection, CD8 T cells develop a dysfunctional or exhausted T-cell phenotype characterized by a higher expression of PD-1 compared to functional T cells. Functional T cells may transiently express negative regulatory molecules, including PD-1, in states of activation; however, persistently high expression indicates an exhausted and dysfunctional T-cell phenotype. Of note, blockade of the PD-1 and ligand (PD-L1) interaction in a mouse model of chronic infection could restore T-cell function, with a resulting reduction in viral load. Subsequent studies identified the same pattern of provoked T-cell dysfunction as a mechanism of tumor evasion of the immune system, leading to the development of therapeutic PD-1 blockade in patients with advanced malignancies.

Pembrolizumab is a humanized PD-1-blocking antibody that blocks the interaction between the PD-1 receptor and its ligands, PD-L1 and PD-L2. It is an IgG4 kappa immunoglobulin blocking antibody. By blocking the PD-1 receptor pathway, the drug may block the PD-1-mediated negative regulatory T-cell signaling in order to allow for T-cell activation to create an antitumor immune response. It is likely that the function of pembrolizumab is much more complex, involving an intricate relationship between PD-1 and other immune modulatory pathways. Notably, PD-1 acts via a distinct mechanism from CTLA-4 to inhibit T-cell activation.

Pembrolizumab has a long elimination half-life of 26 days, with steady-state concentrations reached by 18 weeks on an every 3-week regimen with dose-proportional pharmacokinetic parameters in the dose range of 2–10 mg/kg every 3 weeks. No clinically important differences in pembrolizumab clearance were noted between patients with renal impairment and patients with normal renal function, nor were there differences in clearance between patients with mild hepatic dysfunction and normal function.

Efficacy, safety, and tolerability of pembrolizumab

Melanoma

Patients with advanced melanoma were initially enrolled in a Phase I clinical trial of pembrolizumab for patients with advanced solid tumors (KEYNOTE-001, NCT01295827) in late 2011. When initial efficacy data were first reported in abstract form in 2012 in patients with melanoma, the study protocol had been amended to add additional cohorts of melanoma patients. Accrual proceeded rapidly; 135 patients with advanced melanoma who either had or had not previously been treated with ipilimumab were treated in sequential nonrandomized cohorts with pembrolizumab at doses of 10 mg/kg every 2 weeks, 10 mg/kg every 3 weeks, and 2 mg/kg every 3 weeks. Also, 276 additional patients were subsequently enrolled in two randomized cohorts, and 173 of these patients had disease defined as ipilimumab refractory and the remaining 103 patients were ipilimumab naïve. Within each subset, patients were randomized to receive pembrolizumab at a dose of either 10 or 2 mg/kg every 3 weeks.

Data from the first 135 patients enrolled in KEYNOTE-001 were published in 2013, with a centrally confirmed RECIST objective response rate of 38% and no difference in the response rates of those patients who had and had not received prior ipilimumab. Responses were very durable, with 42 of the 52 responding patients (81%) still receiving treatment at the time of analysis.

Data from the 173 ipilimumab-refractory patients enrolled in the randomized cohorts of KEYNOTE-001 were published in 2014, with no difference in response rates for patients randomized to receive pembrolizumab 2 mg/kg every 3 weeks or 10 mg/kg every 3 weeks. The centrally confirmed objective response rate was 26% in both the dose cohorts of ipilimumab-refractory patients. The lack of dose dependence of response rate was also confirmed in ipilimumab treatment-naïve patients. The centrally confirmed response rates for the 103 ipilimumab-naïve patients randomized to receive pembrolizumab at doses of either 2 mg/kg every 3 weeks or 10 mg/kg every 3 weeks were 33% and 40%, respectively (P=0.4835), which were not statistically different.

Overall, the objective response rate from all 411 patients with advanced melanoma enrolled in all cohorts of KEYNOTE-001 was 34%, with some amount of tumor shrinkage in 72% of patients. Responses were observed in patients with ECOG performance status 0 or 1, LDH level elevated or normal, and with or without brain metastases. Responses were observed in all subsets of patients,
regardless of their M stage, BRAF mutation status, prior BRAF/MEK inhibitor treatment, prior ipilimumab, or prior chemotherapy. There was evidence that patients with a smaller baseline tumor size had a significantly higher response rate and survival compared to patients with a larger baseline tumor size, as defined by the sum of the long dimension of RECIST target lesions at baseline. Baseline tumor size was the only factor predictive of response and prognostic of survival in a multivariate analysis including M stage and prior treatment, among other factors.
Patients with increased PD-L1 expression were more likely to have an objective response compared to patients with no PD-L1 tumor expression, with response rates of 49% and 13%, respectively ($P=0.0007$). PD-L1 positivity was defined as staining in 1% or more of tumor cells.$^{19}$

Of note, overall response rates (ORRs) were slightly higher when assessed by investigator review using the immune-related response criteria$^{23}$ compared to the RECIST response rates reported by the independent central radiology review (37% vs 34%, respectively).$^{22}$ Patients with progression by RECIST but nonprogression by immune-related response criteria had an improved overall survival compared to patients with progressive disease by both criteria. In general, patients with mild asymptomatic radiographic progression and without any unacceptable toxicity can continue treatment with pembrolizumab until repeat radiographic confirmation of progressive disease; in some cases, either a delayed response or a response after initial mild progression or the appearance of new lesions can be observed.

More recently, pembrolizumab has been compared to cytotoxic chemotherapy in a randomized trial (KEYNOTE-002, NCT01704287) in patients with advanced melanoma who had previously been treated with ipilimumab and also a BRAF or MEK inhibitor if BRAF-mutant melanoma. Objective responses were observed in 21% and 25% of patients treated with pembrolizumab 2 and 10 mg/kg every 3 weeks, respectively. There was no statistical difference in the response rates for the two doses; both response rates were higher than that for chemotherapy (4%) as expected ($P<0.0001$), with durable ongoing responses in almost all patients.$^{23}$ Pembrolizumab resulted in significantly smaller changes from baseline compared to chemotherapy in a study of health-related quality of life in KEYNOTE-002 patients, using the global health status/quality-of-life scale of the EORTC QLQ-C30 ($P=0.01$).

Pembrolizumab is generally well tolerated, with serious treatment-related adverse events being rare. There were no treatment-related deaths in the 411 patients with advanced melanoma enrolled in KEYNOTE-001 or in the 540 patients enrolled in KEYNOTE-002. Treatment-related adverse events led to discontinuation in 4% of patients in KEYNOTE-001, with 12% of patients experiencing grade 3–4 treatment-related adverse events. No specific grade 3 or 4 adverse event occurred in more than 2% of patients, with 2% of patients experiencing grade 3 or 4 fatigue and less than 1% of patients experiencing grade 3 or 4 pruritus, rash, diarrhea, nausea, headache, hypothyroidism, decreased appetite, dyspnea, and increased ALT. About 8% of patients did experience hypothyroidism of any grade.

Pembrolizumab gained regulatory approval by the US Food and Drug Association (FDA) in 2014 for the treatment of patients with unresectable stage III or stage IV melanoma with disease progression after ipilimumab and, if BRAF V600-mutant melanoma, a BRAF inhibitor. A randomized Phase III trial of pembrolizumab compared to ipilimumab in previously untreated patients with advanced melanoma has completed accrual (KEYNOTE-006, NCT01866319). Additional trials of pembrolizumab in melanoma are focused on combination therapy approaches with other immune therapies or targeted therapy.

In addition to the data seen with pembrolizumab, nivolumab, the fully human IgG4 antibody targeted against PD-1, has also demonstrated clinical activity in melanoma. An updated analysis of 107 melanoma patients treated with nivolumab demonstrated an ORR of 31%, with a median response duration of 2 years.$^{24}$ Additionally, the combination of nivolumab with other checkpoint inhibitors, including the CTLA-4 antibody, ipilimumab, has also demonstrated promise. In results reported from a Phase I dose escalation study, ORRs appear to be higher with the combination, albeit with some increase in toxicity.$^{25}$

Pembrolizumab in other tumor types

While clinical data to support the efficacy of pembrolizumab have been clearly demonstrated in advanced melanoma, evidence of clinical activity has also been seen in other tumor types, highlighting the potential for the broad application of immuno-oncology across multiple diseases, even those previously not thought to be responsive to immunologic approaches (Table 1).

Non-small cell lung cancer

Traditionally, the mainstay of treatment for advanced non-small cell lung cancer (NSCLC) has been with platinum-based chemotherapy, though an increased understanding of the molecular pathogenesis of the disease has led to multiple novel targets for specific patient subsets in recent years.$^{26–30}$

However, despite the potential for marked responses, for the majority of patients with advanced disease, durable responses remain rare. Historically, immunotherapeutic approaches with vaccines, IL-2, and interferon had shown limited or no benefit in the NSCLC population, and had substantial toxicity.$^{31,32}$ However, early signals of clinical activity with immune checkpoint blockade were seen in NSCLC patient cohorts with the anti-CTLA-4 antibody
Table 1  Selected PD-1-based trials in advanced solid tumors

<table>
<thead>
<tr>
<th>Study</th>
<th>Agent</th>
<th>Patient population</th>
<th>Trial design</th>
<th>Pts (RR)</th>
<th>Median OS (month)</th>
<th>1 year OS (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Melanoma</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Topalian et al</td>
<td>Nivolumab</td>
<td>Previously treated</td>
<td>Phase I, dose escalation/expansion</td>
<td>107 (31)</td>
<td>16.8</td>
<td>62</td>
</tr>
<tr>
<td>Hamid et al</td>
<td>Pembrolizumab</td>
<td>Multiple cohorts; ipilimumab refractory and naive</td>
<td>Phase I, dose escalation/expansion</td>
<td>135 (38)</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td>Robert et al</td>
<td>Pembrolizumab</td>
<td>Ipilimumab refractory</td>
<td>Randomized dose comparison cohort 2 mg/kg vs 10 mg/kg</td>
<td>81 (26)</td>
<td>NR</td>
<td>58</td>
</tr>
<tr>
<td>Ribas et al</td>
<td>Pembrolizumab</td>
<td>Ipilimumab refractory</td>
<td>Phase II randomized, two dose cohorts (2 mg/kg and 10 mg/kg) vs chemotherapy with crossover</td>
<td>180 (21)</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td>Robert et al</td>
<td>Nivolumab</td>
<td>No prior treatment BRAF wild type</td>
<td>Randomized, blinded dacarbazine vs nivolumab</td>
<td>208 (13.9)</td>
<td>10.8</td>
<td>42</td>
</tr>
<tr>
<td><strong>NSCLC</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Brahmer et al</td>
<td>Nivolumab</td>
<td>Previously treated</td>
<td>Phase I, dose escalation/expansion</td>
<td>129 (17)</td>
<td>9.6</td>
<td>42</td>
</tr>
<tr>
<td>Garon et al</td>
<td>Pembrolizumab</td>
<td>Previously treated</td>
<td>Randomized at two dosing schedules</td>
<td>305 (23)</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td>Rizvi et al</td>
<td>Pembrolizumab</td>
<td>No prior treatment PD-L1+ patients</td>
<td>three dosing schedules</td>
<td>45 (26)</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td><strong>RCC</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Topalian et al</td>
<td>Nivolumab</td>
<td>Previously treated</td>
<td>Expansion cohort of Phase I trial; two doses</td>
<td>33 (27)</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td><strong>HNSCC</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Seiwert et al</td>
<td>Pembrolizumab</td>
<td>Previously treated PD-L1+ patients</td>
<td>Phase Ib expansion study</td>
<td>60 (20)</td>
<td>NR</td>
<td>NR</td>
</tr>
</tbody>
</table>

Note: PD-L1+ patients.

Abbreviations: Pts, patients; RR, relative risk; OS, overall survival; NR, not reported; NSCLC, non-small cell lung cancer; RCC, renal cell carcinoma; HNSCC, head and neck squamous cell carcinoma; PD-1, programmed death 1; PD-L1, PD-1 ligand.

ipilimumab as well as with PD-1- and PD-L1-based approaches, suggesting that lung cancers could respond to immunotherapy.

PD-L1 expression has been studied in a number of resected NSCLC specimens, and has been seen in approximately 25%–50% of cases, underscoring a potential role for PD-1-based therapy. In rarer subsets, such as sarcomatoid NSCLC, more than two thirds of tumors express PD-L1. However, the definitive prognostic significance of PD-L1 expression is yet to be determined, with mixed results across reported studies.

Nivolumab was one of the first PD-1 inhibitors to demonstrate promising results in NSCLC. In a cohort of 129 NSCLC patients treated on a Phase I trial, the ORR was 17%, and the median duration of response was 74 weeks. Consistent with prior response patterns to immunotherapy, a subset of patients appeared to derive long-term benefits, with a 1-year survival rate of 42% and a 2-year rate of 24%. These results were especially promising in light of the fact that these patients were heavily pretreated, with more than half having received at least three lines of therapy.

Results of an early-phase trial of pembrolizumab also demonstrate comparable clinical activity in previously treated patients with NSCLC. In this study, patients were randomized to receive pembrolizumab at 10 mg/kg given either every 2 or 3 weeks. A total of 305 patients were eligible based on any detectable level of PD-L1 expression out of 450 patients screened, though some patients whose tumors were negative for PD-L1 were treated in the every 2-week cohort. The (confirmed and unconfirmed) ORR by RECIST 1.1 for patients whose tumors expressed PD-L1 was 26% (CI =15–40) in the 2-week cohort and 21% (CI =13–30) in the 3-week cohort. The majority of responses appeared to be durable. Some responses were still seen in patients whose tumors did not express PD-L1, albeit at lower rates (9%, CI =2–23). Drug-related toxicities were manageable and consistent with agents in this class, the most common being fatigue, decreased appetite, arthralgia, pruritus, and rash. Of note, four cases of drug-related grade 3/4 pneumonitis were seen. Additional patients are currently being enrolled to this study, as well as to a combination study of pembrolizumab with docetaxel for patients with NSCLC who have received at
least one prior therapy (NCT01905657). In the first-line setting, pembrolizumab has also shown promising clinical activity in early-phase studies.\(^4\) In a recent trial, pembrolizumab was administered at three different dosing schedules (2 mg/kg every 3 weeks, 10 mg/kg every 3 weeks, 10 mg/kg every 2 weeks) to 57 patients with advanced NSCLC whose tumors expressed PD-L1 by immunohistochemistry (IHC). Patients had not received any prior therapy for advanced NSCLC, though chemotherapy in the adjuvant setting was allowed if more than 1 year had elapsed. Eighty-four patients were screened, and 57 had tumors that expressed PD-L1; 45 met all eligibility criteria and subsequently enrolled in the study. The best ORR by RECIST for the total population was 26% (14–42). The response rate was 33% (4–78) in the 2 mg/kg cohort and 20% (6–44) and 31% (11–59) in the 10 mg/kg arms (every 3 weeks/every 2 weeks), respectively. Preliminary progression-free survival was 27 weeks, with 56% of patients remaining on treatment at the time of the analysis. Overall, toxicities compared favorably with other regimens and included fatigue, pruritus, diarrhea, and dyspnea. The only grade 3 adverse events were a pericardial effusion and pneumonitis. Larger, randomized studies in the first-line setting are planned or are currently underway.

### Genitourinary cancers

Immunotherapeutic approaches have also been shown to be a viable option for subsets of patients with RCC, historically with high-dose IL-2 or interferon-α2B.\(^46,47\) As in melanoma, high-dose IL-2 was approved for the ability to induce durable complete responses (CRs) in a small proportion of patients; however, the treatment is associated with substantial toxicity. Interferon-α2B is currently considered as a first-line option in combination with bevacizumab for selected patients with clear cell histology.\(^48\) Advances have identified other strategies that have improved outcomes, including antiangiogenic-based therapies as well as targeting mammalian target of rapamycin, though CRs with targeted agents are rare.\(^49\)

Most recently, the potential for PD-1-based therapies has reignited the interest in immunotherapeutic approaches for this disease. Preclinical data suggest that targeting the PD-1 pathway may show promise in RCC as well. In a large retrospective series of nephrectomy specimens, PD-1 was interestingly shown to be expressed by surrounding immune cells, and was present in approximately half of tumors with mononuclear infiltrates.\(^50\) In this study, the presence of PD-1-positive cells was associated with more adverse prognostic features and a worse overall survival, suggesting a role for therapies directed against PD-1. Early clinical activity has also been seen with PD-1-based approaches. In an expansion cohort of 33 RCC patients treated on a Phase I study with nivolumab, objective responses were seen in 24% of patients treated with 1 mg/kg and in 31% of patients treated with 10 mg/kg; additionally, it appeared that many of these responses were durable.\(^52\) Additionally, preclinical observations have suggested that antiangiogenic therapies may affect the tumor microenvironment and allow for synergy with immunotherapies.\(^51,52\) A number of combination strategies are currently underway, including a clinical trial assessing the safety of pembrolizumab in combination with the angiogenesis inhibitor pazopanib (NCT02014636).

In prostate cancer, analyses of prostatectomy specimens have shown that intra- and peritumoral lymphocytes express PD-1, suggesting that manipulation of this pathway could be of potential clinical interest.\(^53,54\) However, to date, there has been limited efficacy seen with PD-1-targeted therapy in castrate-resistant prostate cancer (CRPC), despite some early promise seen with other immunomodulatory agents such as ipilimumab, though limited data exist at this point.\(^55\) In the Phase I trial of nivolumab, 17 patients with metastatic CRPC were treated, and no responses were seen; in the two patients whose tumors were tested, PD-L1 was not expressed, which may be an important predictor of response.\(^35\)

### Head and neck squamous cell carcinoma

Head and neck squamous cell carcinoma is potentially curable in many patients, but recurrent or metastatic disease is difficult to treat, and once diagnosed, median survival is just over 1 year.\(^56,57\) Current therapeutic options are limited, and include standard cytotoxic chemotherapies or the EGFR-targeted antibody cetuximab.\(^58\) In a recent study of patients with recurrent or metastatic head and neck cancer, pembrolizumab demonstrated early signals of promising clinical activity.\(^59\) In this Phase Ib expansion study, patients whose tumors expressed PD-L1 (defined as >1% positive cells in stroma or on tumor cells by IHC) were treated with pembrolizumab at 10 mg/kg every 2 weeks. HPV-positive and HPV-negative patients were treated in separate cohorts. Nearly 80% of patients screened were positive for PD-L1 expression, and 60 patients were treated. Most patients had received at least one prior line of therapy. Overall, pembrolizumab appeared to be well tolerated, and the most common side effects were fatigue and pruritus. There were very few severe adverse events, the most common being rash. Approximately half of patients had a decrease in tumor size, with 20% of patients having a response by RECIST criteria;
the majority of responses appeared to be ongoing. Interestingly, both HPV-positive and HPV-negative patients had similar response rates. In an exploratory analysis, the degree of PD-L1 expression appeared to correlate with response. An additional expansion of this study is currently underway, and Phase III studies in this patient population are planned.

**Colorectal cancer**

Analyses of tumor specimens have shown that a number of gastrointestinal malignancies express PD-L1, including approximately 50% of colorectal cancers (CRCs). More recent analyses have looked at the association of PD-L1 expression in the context of the molecular genetics of CRC, as the role of PD-L1 continues to be defined. In a study of 77 clinically annotated CRC specimens, 47% of sporadic CRC cases had PD-L1-positive intraepithelial lymphocytes. When analyzing this by microsatellite instability (MSI), it was found that MSI-high (MSI-H) tumors had a significantly higher expression of PD-L1-positive lymphocytes when compared to MSI-low (MSI-L) tumors (72% vs 39%, P<0.03). Additionally, MSI-H tumors appeared to have a higher rate of expression of PD-L1 when compared to MSI-L tumors (56% vs 21%, P=0.007). Other studies, however, have shown mismatch repair-deficient CRC to have a lower rate of PD-L1 positivity.

Clinically, there has been early evidence of activity of PD-L1-based therapy in CRC. In a Phase I study of nivolumab that included 39 patients, one patient with metastatic CRC had a durable CR. Interestingly, a pretreatment tumor specimen revealed membranous expression of PD-L1 on rare tumor cells, as well as PD-1-positive CD3+ T cells. Studies are currently underway with nivolumab and pembrolizumab in this patient population. Given the potential differences in susceptibility to modulation with immune checkpoint inhibitors in MSI-H versus MSI-L tumors, a Phase II study of pembrolizumab in patients with CRC is currently enrolling patients (NCT01876511). In this study, patients with MSI-H and MSI-L metastatic CRC will receive pembrolizumab monotherapy in separate cohorts.

**Hematologic malignancies**

A number of other cancers have been shown to express PD-L1, suggesting that immune checkpoint blockade could be beneficial in these malignancies as well. In hematologic malignancies, the PD-1 antibody CT-011 has shown evidence of clinical activity. Of 17 patients, one patient with non-Hodgkin’s lymphoma had a CR. Trials of pembrolizumab in this setting are planned or are currently underway, including studies of pembrolizumab monotherapy as well as a combination study with lenalidomide and low-dose dexamethasone in patients with refractory multiple myeloma.

**Conclusion**

The successful development of PD-L1-based therapy represents a breakthrough in the field of immuno-oncology that has the potential to impact treatment options for many different cancers. Pembrolizumab has demonstrated promising clinical activity in melanoma, and was recently FDA approved for patients whose disease has progressed on ipilimumab and a BRAF inhibitor if indicated. Regarding melanoma, first-line trials are currently underway or have recently been completed. In other malignancies, including NSCLC and RCC, PD-1-targeted agents, including pembrolizumab and nivolumab, have shown clear evidence of antitumor activity. The unique side effect profile of PD-L1-directed therapy makes it a particularly attractive therapeutic strategy for many malignancies, where current standards are often associated with substantial toxicities. Overall, agents in this class, including pembrolizumab, appear to be very well tolerated, and relatively few serious adverse events have been noted. In the future, it is likely that combination strategies will play a key role, and will need to be tailored to specific malignancies. Additionally, continuous exploration of predictive and prognostic markers, as well as a better understanding of mechanisms of resistance, will allow for improved outcomes for many patients.

**Disclosure**

Dr Salama receives research funding from Bristol-Myers Squibb, and has served as a consultant for Roche-Genentech. Dr Gangadhar has received honoraria from Merck. The authors report no other conflicts of interest in this work.

**References**


